Kuhl G, Tangney M
Cancers (Basel). 2025; 17(5).
PMID: 40075571
PMC: 11899205.
DOI: 10.3390/cancers17050723.
Yang Y, Meng Y, Xu Z, Zhang Q, Li M, Kong F
Discov Oncol. 2025; 16(1):299.
PMID: 40069468
PMC: 11896907.
DOI: 10.1007/s12672-025-02038-9.
Chen W, Zhang L, Gao M, Zhang N, Wang R, Liu Y
Front Immunol. 2025; 15():1519034.
PMID: 39840050
PMC: 11747648.
DOI: 10.3389/fimmu.2024.1519034.
Lederer A, Gorrissen N, Nguyen T, Kreutz C, Rasel H, Bartsch F
J Transl Med. 2025; 23(1):34.
PMID: 39789543
PMC: 11716211.
DOI: 10.1186/s12967-024-06012-x.
Ciernikova S, Sevcikova A, Novisedlakova M, Mego M
Cancers (Basel). 2025; 16(24.
PMID: 39766170
PMC: 11674129.
DOI: 10.3390/cancers16244271.
Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.
Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N
Int J Colorectal Dis. 2024; 40(1):1.
PMID: 39731596
PMC: 11682016.
DOI: 10.1007/s00384-024-04790-w.
Back to Roots: Dysbiosis, Obesity, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Obstructive Sleep Apnea-Is There an Objective Connection? A Narrative Review.
Protasiewicz-Timofticiuc D, Badescu D, Mota M, Stefan A, Mitrea A, Clenciu D
Nutrients. 2024; 16(23).
PMID: 39683451
PMC: 11642974.
DOI: 10.3390/nu16234057.
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.
Viel S, Vivier E, Walzer T, Marcais A
Nat Rev Drug Discov. 2024; 24(3):190-208.
PMID: 39668206
DOI: 10.1038/s41573-024-01098-w.
Unraveling the role of gut microbiome in predicting adverse events in neoadjuvant therapy for rectal cancer.
Ma J, Sun S, Cheng X, Meng C, Zhao H, Fu W
Hum Vaccin Immunother. 2024; 20(1):2430087.
PMID: 39623529
PMC: 11622589.
DOI: 10.1080/21645515.2024.2430087.
Tumor-related fungi and crosstalk with gut fungi in the tumor microenvironment.
Wang Y, Wang Y, Zhou Y, Feng Y, Sun T, Xu J
Cancer Biol Med. 2024; 21(11).
PMID: 39601429
PMC: 11667784.
DOI: 10.20892/j.issn.2095-3941.2024.0240.
Narrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic Approach.
Biennier S, Fontaine M, Duquenoy A, Schwintner C, Dore J, Corvaia N
Microorganisms. 2024; 12(11).
PMID: 39597645
PMC: 11596191.
DOI: 10.3390/microorganisms12112256.
A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden.
Rebeck O, Wallace M, Prusa J, Ning J, Evbuomwan E, Rengarajan S
Cell Chem Biol. 2024; 32(1):98-110.e7.
PMID: 39571582
PMC: 11741927.
DOI: 10.1016/j.chembiol.2024.10.013.
Immunostimulation Signaling via Toll-like Receptor 2 Activation: A Molecular Mechanism of OTG1204 In Vitro and In Vivo.
Song H, Jang S, Park M, Kim S, Kang C, Lee J
Nutrients. 2024; 16(21).
PMID: 39519462
PMC: 11547582.
DOI: 10.3390/nu16213629.
Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.
Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E
Heliyon. 2024; 10(20):e39489.
PMID: 39498055
PMC: 11532857.
DOI: 10.1016/j.heliyon.2024.e39489.
Unlocking the potential for microbiome-based therapeutics to address the sustainable development goal of good health and wellbeing.
Gulliver E, Di Simone S, Chonwerawong M, Forster S
Microb Biotechnol. 2024; 17(11):e70041.
PMID: 39487814
PMC: 11531172.
DOI: 10.1111/1751-7915.70041.
Comparison of the Gut Microbiota of Patients Who Improve with Antibiotic Combination Therapy for Ulcerative Colitis and Those Who Do Not: Investigation by Fecal Metagenomic Analyses.
Ohkusa T, Kato K, Sekizuka T, Sugiyama T, Sato N, Kuroda M
Nutrients. 2024; 16(20).
PMID: 39458495
PMC: 11510665.
DOI: 10.3390/nu16203500.
Tertiary Lymphoid Structures in Microorganism-Related Cancer.
Deng S, Yang X, He L, Hou Y, Meng H
Cancers (Basel). 2024; 16(20).
PMID: 39456558
PMC: 11505735.
DOI: 10.3390/cancers16203464.
Microbial Biomarkers in Liquid Biopsy for Cancer: An Overview and Future Directions.
Luo F, Wang X, Ye C, Sun H
Cancer Control. 2024; 31:10732748241292019.
PMID: 39431347
PMC: 11500238.
DOI: 10.1177/10732748241292019.
Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site.
Dorobisz K, Dorobisz T, Pazdro-Zastawny K
Cancers (Basel). 2024; 16(19).
PMID: 39410035
PMC: 11475148.
DOI: 10.3390/cancers16193416.
Gastrointestinal cancer resistance to treatment: the role of microbiota.
Kolahi Sadeghi L, Vahidian F, Eterafi M, Safarzadeh E
Infect Agent Cancer. 2024; 19(1):50.
PMID: 39369252
PMC: 11453072.
DOI: 10.1186/s13027-024-00605-3.